ArcticZymes introduces two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed specifically to meet the evolving demands of the cell, gene and vaccine biomanufacturing sector.
The new SAN HQ ELISA SensoPlus represents a next-generation innovation for detecting trace amounts of SAN HQ nucleases during therapeutic manufacturing processes. With over a fivefold increase in sensitivity compared to its predecessor, this ELISA kit ensures precise monitoring while offering significant workflow benefits. Features such as a reusable format, reduced assay execution times, and lower costs make it an invaluable tool for streamlining biomanufacturing operations.
Complementing SensoPlus, the new SAN HQ GMP neo delivers a GMP-compliant version of ArcticZymes' widely utilized SAN HQ Triton FREE. This product reflects ArcticZymes' commitment to expanding its portfolio of high-performance nucleases, providing biomanufacturers the flexibility to select solutions tailored to their unique production needs. By adding GMP variants to its portfolio, ArcticZymes is proactively addressing the increasingly stringent regulatory requirements of the biomanufacturing industry, enabling partners to achieve compliance with global standards while optimizing their production processes.
“With SAN HQ ELISA SensoPlus and SAN HQ GMP neo, we are responding to the critical performance and regulatory demands of the cell, gene, and vaccine biomanufacturing markets,” said Michael Akoh, CEO of ArcticZymes. “These innovations underscore our dedication to empowering biomanufacturers with reliable, high-quality tools that facilitate compliance and operational efficiency. ArcticZymes continues to solidify its role as a trusted partner for global leaders in therapeutic development and production.”
For further information, please contact us at:
Børge Sørvoll, CFO
Michael Akoh, CEO
